Advertisement
ABSI vs RXRX
Which Stock Would AI Choose? Absci Corporation (ABSI) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- ABSI has shown significantly stronger momentum, delivering a triple-digit year-to-date gain on positive clinical data and a strategic investment from Eli Lilly, while RXRX has traded lower over the trailing twelve months.
- ABSI carries a "Strong Buy" consensus from Wall Street, whereas RXRX holds a "Moderate Buy" rating, reflecting differing analyst conviction.
- Both companies are AI-driven drug developers, but ABSI is concentrated around a single lead asset, while RXRX operates a diversified platform with a broader pipeline.
- Recent financing activity highlights a key contrast: ABSI raised capital at a premium through strategic investors, while RXRX priced a dilutive follow-on equity offering.
- Tickeron AI Verdict: ABSI is the current preferred ticker, based on stronger trend consistency, positive catalysts, and more favorable relative positioning.
- For more on each name, explore ABSI Major News and ABSI Today's Price Move, plus RXRX Major News and RXRX Today's Price Move.
- To see which strategies are performing best right now, explore Trending AI Robots.
Introduction
Both ABSI (Absci Corporation) and RXRX (Recursion Pharmaceuticals) sit at the intersection of artificial intelligence and drug discovery, a theme that has drawn intense investor interest. Yet these two clinical-stage biotechs have taken sharply different paths in the current market environment. This stock comparison examines their business models, recent price behavior, growth drivers, and risk profiles to help growth-oriented investors, biotech traders, and anyone tracking AI-enabled healthcare understand how these names stack up. Because both companies remain pre-profit and heavily dependent on clinical milestones and financing, the contrast in their recent relative performance and market positioning is especially instructive for those evaluating where momentum and conviction currently lie.
ABSI Overview and Recent Performance
Absci Corporation is a clinical-stage biopharmaceutical company that applies generative AI to design and develop antibody therapeutics. Its pipeline is anchored by ABS-201, a prolactin-receptor (PRLR)-targeting antibody being evaluated for androgenetic alopecia (hair loss) and endometriosis. In recent weeks, ABSI has been one of the standout performers in the AI drug-discovery space, with its share price surging sharply on encouraging interim Phase 1 data from the HEADLINE study and on a capital raise anchored by Eli Lilly, which committed a substantial investment and development support tied to the program. These developments extended the company's cash runway and reinforced its clinical narrative, helping the stock post a roughly triple-digit year-to-date gain. That momentum has been volatile, however, with pullbacks as the broader AI biotech trade cools. Wall Street maintains a predominantly positive stance, with an average price target well above recent trading levels.
RXRX Overview and Recent Performance
Recursion Pharmaceuticals is a clinical-stage "TechBio" company that combines automated experimentation, large proprietary datasets, and machine learning to industrialize drug discovery across a diversified pipeline. Recent weeks brought a wave of notable announcements: Sanofi optioned a potential first-in-class oral small molecule, triggering a milestone payment with hundreds of millions in additional potential milestones, and the company priced an oversubscribed follow-on offering of roughly $200 million. Recursion also reported encouraging data from its REC-4881 program in familial adenomatous polyposis (FAP), showing meaningful reductions in polyp burden. Despite these catalysts, RXRX has lagged, trading down over the trailing twelve months and carrying only a modest year-to-date gain, with recent dilution weighing on sentiment. The shares also changed hands at a roughly 40% loss over the past year before the latest rally.
Trending AI Robots
Tickeron operates hundreds of AI-powered trading bots that collectively monitor and trade thousands of different tickers, each with its own strategy, timeframe, and risk profile. Rather than overwhelming users with every available option, Tickeron curates the most suitable bots for current market conditions into a dedicated Trending AI Robots section. These automated systems vary in approach — from short-term momentum strategies to longer-horizon trend following — and each is backed by its own performance statistics and track record. The curated list is designed to surface the bots showing the strongest alignment with prevailing market behavior, helping traders filter a large universe down to a manageable set of candidates. Explore the Trending AI Robots page to review current top performers and see which strategies are resonating with today's market.
Head-to-Head Comparison
The core contrast between these two AI biotechs is breadth versus concentration. RXRX runs a platform business with five clinical-stage programs and multiple large pharma collaborations, offering diversification and repeatable milestone economics — but that breadth has yet to translate into strong stock performance, and recent equity raises have diluted shareholders. ABSI, by contrast, is a more concentrated story centered on a single lead asset, which concentrates both upside and risk around upcoming proof-of-concept readouts. On momentum, ABSI has clearly outperformed, while RXRX has struggled despite a comparable flow of positive headlines. Sector exposure is similar, but market sentiment and analyst conviction currently favor ABSI. Risk profiles differ too: RXRX faces platform-scale execution and dilution risk, whereas ABSI faces binary clinical-outcome risk tied to one drug.
Tickeron AI Verdict
Based on observable factors — trend consistency, momentum, analyst conviction, and near-term catalysts — Tickeron's AI would currently lean toward ABSI as the more favorably positioned ticker in this comparison. The stock's stronger relative performance, positive clinical signal, and non-dilutive strategic backing indicate more durable current momentum than RXRX, whose progress has been partly offset by dilution and a weaker technical trend. This is a probabilistic assessment rather than a definitive claim; concentrated clinical risk and elevated valuations mean the ranking could shift quickly if data or sentiment change. Traders should weigh these signals against their own risk tolerance and time horizon.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABSI is a Hold and RXRX is a Hold.
ABSI in upward trend: price rose above 50-day moving average on October 26, 2026
ABSI moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 48 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ABSI as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for ABSI just turned positive on October 27, 2026. Looking at past instances where ABSI's MACD turned positive, the stock continued to rise in 41 of 47 cases over the following month. The odds of a continued upward trend are 87%.
The 10-day moving average for ABSI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +8.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 242 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 142 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABSI moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 58 cases where ABSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
ABSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.307) is normal, around the industry mean (2.904). P/E Ratio (-13.266) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RXRX's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Oscillator for RXRX moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 25 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 57 cases where RXRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RXRX as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
RXRX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 207 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 108 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.274) is normal, around the industry mean (2.904). P/E Ratio (-3.880) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| ABSI | RXRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| Advances ODDS (%) | 2 days ago 90% | 9 days ago 83% |
| Declines ODDS (%) | 4 days ago 88% | 3 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABSI’s FA Score shows that 0 FA rating(s) are green while RXRX’s FA Score has 0 green FA rating(s).
- ABSI’s FA Score: 0 green, 5 red.
- RXRX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABSI’s TA Score shows that 6 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).
- ABSI’s TA Score: 6 bullish, 4 bearish.
- RXRX’s TA Score: 5 bullish, 5 bearish.
Price Growth
ABSI (@Biotechnology) experienced а -11.78% price change this week, while RXRX (@Biotechnology) price change was -10.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.61%. For the same industry, the average monthly price growth was -14.13%, and the average quarterly price growth was -21.03%.
Reported Earning Dates
ABSI is expected to report earnings on Nov 12, 2026.
RXRX is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (-8.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RXRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To RXRX | 1D Price Change % | ||
|---|---|---|---|---|
| RXRX | 100% | +5.43% | ||
| CRSP - RXRX | 65% Loosely correlated | +3.57% | ||
| PRME - RXRX | 61% Loosely correlated | +9.23% | ||
| ABSI - RXRX | 59% Loosely correlated | +4.80% | ||
| BEAM - RXRX | 59% Loosely correlated | +5.55% | ||
| DNA - RXRX | 57% Loosely correlated | +8.27% | ||
More | ||||